Saturday, October 31, 2026

Marathon Stock Plummets 12% As Investors Lose Faith

ViaNews Editorial Team

February 20, 2024

Marathon Stock Plummets 12% As Investors Lose Faith

(VIANEWS) - Marathon Shares Have Plummeted by 12.21% to EUR23.65, Contributing to NASDAQ's Decrease. Marathon Patent Group (NASDAQ: MARA) shares experienced an unprecedented 12.21% drop to EUR23.65 at 12:34 EST Tuesday afternoon after two consecutive sessions of losses, further contributing to an overall decrease of 1.55% for NASDAQ as it currently sits at EUR15,530.59. Marathon recently closed at EUR26.94, representing a drop of 13.93% since reaching a 52-week high of EUR31.30. This decline may signal an overall downward trend in the stock market.

About Marathon

Marathon Digital Holdings, Inc. is an American digital asset technology company established in 2010. Since 2010, they specialize in mining digital assets with an emphasis on blockchain ecosystem. Formerly known as Marathon Patent Group Inc, in February 2021 the name changed to Marathon Digital Holdings Inc and currently located in Fort Lauderdale Florida with strong expertise to generate valuable digital assets that contribute to growth of blockchain ecosystem.

Yearly Analysis

Marathon's stock (MARA) is currently trading at EUR23.65, significantly below its 52-week high of EUR31.30 but above its low of EUR5.13 from one year ago. This indicates a significant price fluctuation over this timeframe. Marathon's sales growth projections show an astounding 217.9% surge by 2023 and more moderate 69.6% growth by 2024 - significantly outpacing industry average rates, signaling optimism for its future prospects. Marathon's EBITDA, which measures the company's operating profitability, currently stands at 17.65. This indicates that Marathon is making a decent amount of profit through its operations - something investors will find encouraging. Overall, Marathon's stock appears undervalued relative to its 52-week high price; however, its promising growth prospects and healthy EBITDA could make it an appealing investment opportunity for those willing to take some risk.

Technical Analysis

Investors have seen Marathon's stock price surge above its 50-day and 200-day moving averages, currently EUR26.50 and EUR19.80, in recent months. This indicates a positive upward trend; however, volume traded today was significantly less than usual at 41.67 million shares versus its usual volume of 80.47 million. Volatility for this stock has also increased, with an average intraday variation over the past week of 1.73%, 2.66% for last month and 6.61% over quarter. This may contribute to its overbought condition as indicated by stochastic oscillator. Overall, Marathon's stock price appears to be on an upward trajectory; however, investors should remain wary of any potential pullback given its overbought status and lower-than-average trading volume. Therefore, investors would do well to pay attention to these indicators over the coming weeks in order to monitor Marathon's performance and potentially profit from it.

Quarter Analysis

Marathon's sales growth has been impressive, with an astounding 404.2% increase for this quarter and 238.2% growth projection for next quarter - an estimate for each being approximately 107.55% and 300%, respectively. Furthermore, they've experienced year-on-year revenue growth of 671.1% (current total of 259.16M for twelve trailing months). Overall these numbers suggest strong development for Marathon in its near future.

Equity Analysis

Based on Marathon's financial information, its estimated EPS for the most recent twelve-month period stands at EUR-3.08 indicating that it is not currently producing profits for its shareholders. Additionally, the company's return on equity (ROE) for the past twelve months stands at negative -42.13% - an indication that they are failing to utilize shareholder's equity effectively in order to generate profits and is therefore an alarm bell for investors. Overall, Marathon's current financial metrics point out the difficulty it faces with regard to profitability and return on equity - issues which could negatively impact its stock performance in the future. Investors should carefully consider this information prior to making investment decisions.

More news about Marathon (MARA).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com